ASH Day 1 highlights and lowlights Part 2
The first day of ASH oral presentations brought some unexpected surprises from several quarters, both good and not so good.
In this second review of the highlights, we cover some important translational research, as well as various clinical studies in both AML and multiple myeloma.
The latter focuses on discussing some subtleties and nuances to watch out for in the BCMA CAR T cell space. A number of people have been declaring ‘wins’ to different products across the board, but it’s way too early to call at this stage given phase 1 trials do not always predict what will happen in pivotal registration trials. There are also some challenges to address along the way so we put these findings in context.
To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the ASH meeting — subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
